Lyka Labs Share Price Today (LYKALABS)
TODAY IN ONE LINE
With a market cap of ₹225.05 Cr., it trades at a P/E of -20.64. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Lyka Labs flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Promoter HoldingPromoters hold 58.2% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Rising Receivables vs SalesReceivables grew 48.4% outpacing sales growth of 24.6%
Latest Lyka Labs News
What changed recently?
Recent events, corporate actions, and announcements.
Lyka Labs Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Lyka Labs Limited, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Lyka Labs Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Lyka Labs Limited — derived from the live tape, not yesterday's close.
Lyka Labs Limited last traded at ₹74.83 with an intraday range of ₹72.7–₹77 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹74.83| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 85.59 | +10.76 | +14.37% |
| R3 | 81.29 | +6.46 | +8.63% |
| R2 | 79.14 | +4.31 | +5.76% |
| R1 | 76.99 | +2.16 | +2.88% |
| PIVOT | 74.84 | 0.01 | 0.02% |
| CURRENT | 74.83 | — | — |
| S1 | 72.69 | -2.14 | -2.86% |
| S2 | 70.54 | -4.29 | -5.73% |
| S3 | 68.39 | -6.44 | -8.61% |
| S4 | 64.09 | -10.74 | -14.36% |
LYKALABS is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹–₹
Trading Above opening range, showing Bullishness
Lyka Labs Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Lyka Labs Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Lyka Labs Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹225.05 Cr. and reported EPS of ₹-2.81.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 138 | 128 ▼ 7.3% |
| Sales Growth YoY %Derived | 24.55% | -7.26% |
| Other Income | 2 | 3 ▲ 56.7% |
| Total Income | 141 | 132 ▼ 6.2% |
| 56 | 50 ▼ 9.7% | |
| Gross ProfitDerived | 83 | 78 ▼ 5.6% |
| Gross Margin %Derived | 59.86% | 60.92% |
| 65 | 82 ▲ 25.8% | |
| EBITDA (Operating Profit)Derived | 18 | -3 ▼ 119.4% |
| OPM %Derived | 12.95% | -2.71% |
| 9 | 12 ▲ 30.4% | |
| Profit Before Tax (PBT) | 11 | -12 ▼ 205.9% |
| 3 | -1 ▼ 142.1% | |
| Effective Tax %Derived | 28.69% | 11.41% |
| Total Profit for Period | 8 | -10 ▼ 231.5% |
| Less: Non-controlling Interests | -0 | -0 ▼ 412.7% |
| Net Profit (Owner's PAT)Derived | 8 | -10 ▼ 225.2% |
| Net Profit Margin %Derived | 5.79% | -7.81% |
| PAT Growth YoY %Derived | 405.74% | -225.21% |
| Earnings Per Share (EPS ₹) | 2.24 | -2.81 ▼ 225.4% |
| Diluted Shares Outstanding (Cr) | 4 | 4 ▲ 0.0% |
| Share of Profit from Associates/JVs | — | — |
| Other Comprehensive Income (Net of Tax) | 0 | -0 ▼ 179.6% |
| Total Expenses (incl. D&A & Interest) | 130 | 144 ▲ 10.9% |
| Material Cost % of RevenueDerived | 26.77% | 24.74% |
| Employee Cost % of RevenueDerived | 25.01% | 32.58% |
| Other Cost % of RevenueDerived | 21.90% | 31.05% |
| Interest Coverage (x)Derived | 4.91x | -3.59x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 61 | 71 ▲ 16.8% | 61 ▼ 13.2% | 86 ▲ 40.4% | 194 ▲ 125.0% | 93 ▼ 52.0% | 111 ▲ 19.5% | 138 ▲ 24.6% | 128 ▼ 7.3% | |
| Sales Growth YoY %Derived | — | 16.77% | -13.23% | 40.44% | 125.02% | -52.05% | 19.47% | 24.55% | -7.26% | |
| Other Income | 2 | 2 ▼ 2.0% | 3 ▲ 47.7% | 2 ▼ 49.4% | 2 ▲ 34.1% | 3 ▲ 62.4% | 1 ▼ 57.2% | 2 ▲ 53.4% | 3 ▲ 56.7% | |
| Total Income | 63 | 73 ▲ 16.1% | 65 ▼ 11.5% | 88 ▲ 36.1% | 196 ▲ 123.4% | 96 ▼ 50.8% | 113 ▲ 16.8% | 141 ▲ 24.9% | 132 ▼ 6.2% | |
29 | 39 ▲ 33.6% | 36 ▼ 8.8% | 38 ▲ 6.1% | 53 ▲ 39.5% | 38 ▼ 29.1% | 45 ▲ 19.4% | 56 ▲ 23.9% | 50 ▼ 9.7% | ||
| Gross ProfitDerived | 31 | 32 ▲ 1.0% | 26 ▼ 18.8% | 48 ▲ 88.4% | 141 ▲ 192.2% | 56 ▼ 60.7% | 66 ▲ 19.5% | 83 ▲ 25.0% | 78 ▼ 5.6% | |
| Gross Margin %Derived | 51.53% | 44.56% | 41.72% | 55.98% | 72.71% | 59.65% | 59.66% | 59.86% | 60.92% | |
36 | 33 ▼ 8.2% | 29 ▼ 12.4% | 29 ▼ 2.4% | 40 ▲ 39.7% | 39 ▼ 3.2% | 51 ▲ 30.9% | 65 ▲ 28.3% | 82 ▲ 25.8% | ||
| EBITDA (Operating Profit)Derived | -5 | -2 ▲ 63.4% | -4 ▼ 93.5% | 20 ▲ 636.6% | 101 ▲ 413.9% | 17 ▼ 83.4% | 16 ▼ 6.7% | 18 ▲ 14.1% | -3 ▼ 119.4% | |
| OPM %Derived | -8.54% | -2.68% | -5.97% | 22.82% | 52.12% | 18.09% | 14.13% | 12.95% | -2.71% | |
21 | 13 ▼ 37.8% | -5 ▼ 138.6% | 33 ▲ 743.9% | 31 ▼ 6.6% | 19 ▼ 39.8% | 17 ▼ 7.2% | 9 ▼ 47.7% | 12 ▲ 30.4% | ||
| Profit Before Tax (PBT) | -20 | -15 ▲ 23.0% | -62 ▼ 301.2% | -14 ▲ 77.1% | 59 ▲ 518.9% | -13 ▼ 122.2% | -1 ▲ 92.9% | 11 ▲ 1291.4% | -12 ▼ 205.9% | |
-1 | -9 ▼ 772.6% | 1 ▲ 108.1% | -4 ▼ 650.7% | 21 ▲ 613.2% | -0 ▼ 100.1% | 2 ▲ 9119.8% | 3 ▲ 89.2% | -1 ▼ 142.1% | ||
| Effective Tax %Derived | 5.19% | 58.82% | -1.19% | 28.66% | 35.11% | 0.14% | -180.63% | 28.69% | 11.41% | |
| Total Profit for Period | -19 | -6 ▲ 66.6% | -63 ▼ 885.7% | -12 ▲ 81.5% | 39 ▲ 437.5% | -13 ▼ 133.7% | -3 ▲ 80.1% | 8 ▲ 402.7% | -10 ▼ 231.5% | |
| Less: Non-controlling Interests | -2 | -1 ▲ 58.3% | -2 ▼ 178.4% | — ▲ 100.0% | — | 0 | — ▼ 100.0% | -0 | -0 ▼ 412.7% | |
| Net Profit (Owner's PAT)Derived | -17 | -6 ▲ 67.4% | -61 ▼ 979.9% | -12 ▲ 80.9% | 39 ▲ 437.5% | -13 ▼ 133.9% | -3 ▲ 80.2% | 8 ▲ 405.7% | -10 ▼ 225.2% | |
| Net Profit Margin %Derived | -28.40% | -7.92% | -98.56% | -13.40% | 20.09% | -14.20% | -2.36% | 5.79% | -7.81% | |
| PAT Growth YoY %Derived | — | 67.44% | -979.93% | 80.91% | 437.53% | -133.88% | 80.17% | 405.74% | -225.21% | |
| Earnings Per Share (EPS ₹) | -6.12 | -2.26 ▲ 63.1% | -21.10 ▼ 833.6% | -4.03 ▲ 80.9% | 13.59 ▲ 437.2% | -4.30 ▼ 131.6% | -0.79 ▲ 81.6% | 2.24 ▲ 383.5% | -2.81 ▼ 225.4% | |
| Diluted Shares Outstanding (Cr) | 3 | 3 ▲ 0.0% | 3 ▲ 2.0% | 3 ▲ 0.0% | 3 ▲ 0.0% | 3 ▲ 7.0% | 3 ▲ 7.8% | 4 ▲ 7.9% | 4 ▲ 0.0% | |
| Share of Profit from Associates/JVs | — | — | — | — | 1 | — ▼ 100.0% | — | — | — | |
| Other Comprehensive Income (Net of Tax) | -0 | 0 ▲ 163.4% | -0 ▼ 218.1% | 0 ▲ 133.1% | 0 ▲ 27.7% | -0 ▼ 125.9% | 0 ▲ 390.4% | 0 ▲ 71.6% | -0 ▼ 179.6% | |
| Total Expenses (incl. D&A & Interest) | 83 | 88 ▲ 6.6% | 126 ▲ 43.1% | 102 ▼ 19.3% | 137 ▲ 34.3% | 110 ▼ 19.9% | 114 ▲ 3.6% | 130 ▲ 14.1% | 144 ▲ 10.9% | |
| Material Cost % of RevenueDerived | 30.49% | 21.27% | 21.89% | 14.28% | 13.88% | 24.79% | 28.91% | 26.77% | 24.74% | |
| Employee Cost % of RevenueDerived | 28.02% | 20.75% | 22.56% | 16.89% | 9.30% | 19.99% | 24.07% | 25.01% | 32.58% | |
| Other Cost % of RevenueDerived | 32.05% | 26.49% | 25.13% | 16.27% | 11.29% | 21.57% | 21.46% | 21.90% | 31.05% | |
| Interest Coverage (x)Derived | -2.07x | -1.28x | -0.58x | 0.44x | 4.16x | 0.23x | 0.60x | 4.91x | -3.59x |
Lyka Labs segment analysis : revenue and profit mix.
Disclosed business segments at Lyka Labs with their share of revenue and profit, switchable between consolidated and standalone reporting.
Lyka Labs discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Lyka Labs Limited.
Our AI distills the core fundamental drivers supporting Lyka Labs Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Lyka Labs Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Promoter holding increased to 58%, indicating strong management confidence overall.
Low debt-to-equity ratio (~0.3) reflects prudent leverage and overall stability.
Quarterly sales grew 9.7% YoY, showing demand expansion in markets.
Operating cash flow positive 5.09 Cr in 2026, supporting liquidity.
Diverse product portfolio spans dermatology, gastroenterology, and nutraceuticals, boosting resilience.
Key Risks.
Negative operating margin of -9.43% signals cost inefficiencies, profitability concerns.
Net margin -7.81% indicates ongoing profitability pressure for shareholders today.
High P/E of 45x suggests overvaluation relative to peers market.
Flat 5‑year revenue growth of 0% signals stagnation in growth.
Zero dividend yield limits income for income‑seeking investors and returns.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Lyka Labs Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Lyka Labs Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Lyka Labs Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Lyka Labs Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Lyka Labs Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Lyka Labs Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Lyka Labs Limited stood at 62.2% of traded volume, against a 20-day average of 63.2%.
Lyka Labs announcements: results, concalls, ratings, M&A.
Filings Lyka Labs sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Lyka Labs files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 60 documents below.
Copy of Newspaper Publication
Lyka Labs Limited has informed the Exchange about Copy of Newspaper Publication
General Updates
Lyka Labs Limited has informed the Exchange about General Updates
General Updates
Lyka Labs Limited has informed the Exchange about General Updates
Shareholders meeting
Lyka Labs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 10, 2026
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Lyka Labs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Investor decks & rating reports.
Lyka Labs dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Lyka Labs has declared, sequenced by announce and record date.
Lyka Labs corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Lyka Labs Limited: business, sector, key facts.
What Lyka Labs Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Lyka Labs Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: LYKALABS, BSE: 500259.
Lyka Labs Limited is an Indian pharmaceutical company with a comprehensive business model encompassing the development, manufacturing, and marketing of a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Their product portfolio spans numerous therapeutic areas, demonstrating a significant presence in the Indian pharmaceutical market and beyond.
The company's manufacturing capabilities are extensive, producing a diverse array of formulations including topical treatments (emollients, steroids, antifungals, antibacterials, acne medications), pain relievers, anti-aging products, hair care solutions, and sunscreens. Beyond dermatological products, Lyka Labs manufactures products for various other therapeutic segments, such as gastroenterology, anti-infectives, and even intensive care medications, showcasing their versatility in manufacturing different dosage forms.
Lyka Labs' product offerings extend to a broad spectrum of dosage forms, including injections, creams, ointments, foams, gels, and lotions, catering to a wide range of patient needs and administration preferences. This diverse portfolio also includes nutraceuticals, indicating a focus on both pharmaceutical and health supplement markets.
A significant aspect of Lyka Labs' business is its provision of contract manufacturing services to other large pharmaceutical companies. This service extends beyond simply manufacturing; it also includes offering crucial technical assistance, encompassing manufacturing know-how, facility support, and the provision of vital technical data such as stability testing data, impurity profiles, and bioequivalence (BA/BE) clinical study data. This demonstrates a commitment to providing comprehensive support to its clients.
Finally, Lyka Labs' operations extend beyond the domestic market, as the company actively exports its products internationally, indicating a successful penetration of international markets and a growing global presence. In summary, Lyka Labs is a well-established player in the pharmaceutical industry, combining internal product development and manufacturing with a significant contract manufacturing and technical services division, all while engaging in both domestic and international markets.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Lyka Labs Limited (LYKALABS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Lyka Labs Limited (LYKALABS)?
The current share price of Lyka Labs Limited (LYKALABS) is ₹74.83. Today, the stock has gained by ₹0.88 (1.19%), trading in a range of ₹72.7 to ₹77. The stock opened at ₹74.81 with a trading volume of 88,556 shares.
02Is Lyka Labs Limited stock a good investment for long-term?
Lyka Labs Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹225.05 crores, P/E ratio of -20.64, ROE of 0.00%, and ROCE of 9.91%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Lyka Labs Limited stock?
The 52-week high price of Lyka Labs Limited (LYKALABS) is ₹121.44, while the 52-week low is ₹44.1. Currently trading at ₹74.83, the stock is 39.7% away from its 52-week low and 38.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Lyka Labs Limited stock at the current price?
Whether to buy Lyka Labs Limited stock at ₹74.83 depends on multiple factors. The stock is currently trading with a P/E ratio of -20.64 and P/B ratio of 2.24. Today's performance shows a gain of 1.19%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Lyka Labs Limited and when is the next dividend?
Lyka Labs Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹74.83, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Lyka Labs Limited?
Lyka Labs Limited's key financial metrics include: P/E Ratio: -20.64, P/B Ratio: 2.24, ROE: 0.00%, ROCE: 9.91%, Dividend Yield: 0.00%, EPS: ₹-2.81, Book Value: ₹25.87, and Debt-to-Equity: 0.00. The company's market cap stands at ₹225.05 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Lyka Labs Limited stock performing today in the market?
Lyka Labs Limited stock opened at ₹74.81 and is currently trading at ₹74.83, showing a gain of ₹0.88 (1.19%). The intraday high is ₹77 and low is ₹72.7. The trading volume stands at 88,556 shares, indicating moderate market participation today.
08What is the P/E ratio of Lyka Labs Limited and what does it indicate?
Lyka Labs Limited has a Price-to-Earnings (P/E) ratio of -20.64, which means investors are willing to pay ₹-20.64 for every ₹1 of earnings. With an EPS of ₹-2.81, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Lyka Labs Limited (LYKALABS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.